Biogen
NEWS
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Here is a look at the life science companies viewed as the most innovative in the world.
Despite the recent dismal news regarding Alzheimer’s drug development, the U.S. Food and Drug Administration (FDA) recently proposed new guidelines for developing drugs for the disease.
Shares dropped by 9.1 percent, the biggest intraday decline since June 2016.
This is a market like the world has never seen.
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
The effort was announced last week by the Henri A. Termeer Tribute Committee.
News of the buy was tucked away in the company’s fourth-quarter financial report.
The year is already off to a good start with mergers and acquisitions in the biopharma industry.
JOBS
IN THE PRESS